. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Mycoses. 2014 Oct 8;57(12):718–733. doi: 10.1111/myc.12265

Table 2.

Investigational antifungal agents currently in clinical trials for Candida spp. infections.

Compound	Company	Structure	Indication	Stage of development	Mechanism of action
Isavuconazole	Originator: Basilea Pharmaceutica Licensee: Astellas	Antifungal triazole	Candidemia, other invasive Candida spp. infections, Aspergillus infection, Mucormycosis infection	Phase 3	Inhibitor of lanosterol 14α-demethylase
Albaconazole	Originator: Palau Pharma Licensee: Actavis	Antifungal triazole	Vulvovaginal candidiasis, tinea pedis, onychomycosis	Phase 2	Inhibitor of lanosterol 14α-demethylase
MK-3118/ SCY-078	Originator :Scynexis	Derivative of enfumafungin (hemiacetal triterpene glycoside)		Phase 1	Inhibitor of (1→3)-β-D- glucan synthase
VT-1161	Viamet	Not in public domain	Onychomycosis, candidiasis	Phase 2	Inhibitor of lanosterol demethylase (CYP51)
T-2307	Toyama	Arylamidine		Phase 1	Impairment of mitochondrial function